Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReade, Michael Cen
dc.contributor.authorO'Sullivan, Kimen
dc.contributor.authorBates, Samanthaen
dc.contributor.authorGoldsmith, Donnaen
dc.contributor.authorAinslie, William R S T Jen
dc.contributor.authorBellomo, Rinaldoen
dc.identifier.citationCritical Care 2009; 13(3): R75en
dc.description.abstractAgitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy. Use of conventional sedatives to control agitation can preclude extubation. Dexmedetomidine, a novel sedative and anxiolytic agent, may have particular utility in these patients. We sought to compare the efficacy of haloperidol and dexmedetomidine in facilitating extubation.We conducted a randomised, open-label, parallel-groups pilot trial in the medical and surgical intensive care unit of a university hospital. Twenty patients undergoing mechanical ventilation in whom extubation was not possible solely because of agitated delirium were randomised to receive an infusion of either haloperidol 0.5 to 2 mg/hour or dexmedetomidine 0.2 to 0.7 microg/kg/hr, with or without loading doses of 2.5 mg haloperidol or 1 mug/kg dexmedetomidine, according to clinician preference.Dexmedetomidine significantly shortened median time to extubation from 42.5 (IQR 23.2 to 117.8) to 19.9 (IQR 7.3 to 24) hours (P = 0.016). Dexmedetomidine significantly decreased ICU length of stay, from 6.5 (IQR 4 to 9) to 1.5 (IQR 1 to 3) days (P = 0.004) after study drug commencement. Of patients who required ongoing propofol sedation, the proportion of time propofol was required was halved in those who received dexmedetomidine (79.5% (95% CI 61.8 to 97.2%) vs. 41.2% (95% CI 0 to 88.1%) of the time intubated; P = 0.05). No patients were reintubated; three receiving haloperidol could not be successfully extubated and underwent tracheostomy. One patient prematurely discontinued haloperidol due to QTc interval prolongation.In this preliminary pilot study, we found dexmedetomidine a promising agent for the treatment of ICU-associated delirious agitation, and we suggest this warrants further testing in a definitive double-blind multi-centre NCT00505804.en
dc.subject.otherDelirium.drug therapy.etiologyen
dc.subject.otherDexmedetomidine.adverse effects.therapeutic useen
dc.subject.otherDopamine Antagonists.adverse effects.therapeutic useen
dc.subject.otherDrug-Related Side Effects and Adverse Reactionsen
dc.subject.otherHaloperidol.adverse effects.therapeutic useen
dc.subject.otherHypnotics and Sedatives.adverse effects.therapeutic useen
dc.subject.otherIntubation, Intratrachealen
dc.subject.otherMiddle Ageden
dc.subject.otherPilot Projectsen
dc.subject.otherPsychomotor Agitation.drug therapy.etiologyen
dc.subject.otherRespiration, Artificialen
dc.titleDexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.en
dc.typeJournal Articleen
dc.identifier.journaltitleCritical Careen
dc.identifier.affiliationDepartment of Intensive Care Medicine, Austin Hospital and the University of Melbourne, 145 Studley Road, Heidelberg, Victoria 3084, Australiaen
dc.type.austinJournal Articleen, Rinaldo
item.openairetypeJournal Article-
item.fulltextWith Fulltext- Care- Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
19454032.pdf227.28 kBAdobe PDFThumbnail
Show simple item record

Page view(s)

checked on Mar 4, 2024


checked on Mar 4, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.